Clinical trial with Manremyc® food supplement to promote immunity to SARS-CoV-2

Type of project

Clinical trial to evaluate the protection of the RUTI® vaccine in health professionals at risk of infection with 200 receiving the vaccine and 100 receiving a placebo.

Brief description and objectives

In the absence of a definitive vaccine and in order to accelerate the availability of drugs to combat the SARS-CoV-2 virus the Catalan public health system has fast-tracked studies to re-purpose known and tested therapies and test their efficacy against the virus. This study uses a food-supplement already in advanced clinical trials to prevent tubeculosis infections. The administration of Manremyc® generates a balanced immune response and prevents inflammation and lesions in the lungs. This study will text whether it affords more immunity to health professionals. Manremyc® has been developed by a spin-off company of the IGTP (Manresana de Micobacteriologia, s.l.).

Project leader

Pere-Joan Cardona, IGTP

Project members

With the collaboration of the IDIAP-Jordi Gol Foundation
Reig Jofre
 

Projected timing

6 months

Funding bodies

The Ministry of Health and the Department of Research and Innovation of the Department of Health (DGRIS) of the Government of Catalonia with the collaboration of AQuAS and Biocat

Associated News

The IGTP coordinates a clinical trial to reduce the number of infections by SARS-CoV-2